Citation, DOI, disclosures and article data
At the time the article was created Frank Gaillard had no recorded disclosures.View Frank Gaillard's current disclosures
Budd-Chiari syndrome, also known as hepatic venous outflow obstruction (HVOO), refers to the clinical picture that occurs when there is partial or complete obstruction of the hepatic veins.
There is no clear consensus regarding the number of occluded veins, some authors claim that there should be at least one occluded hepatic vein 7, others state that there are no significant hemodynamic changes if only one vein is occluded therefore clinical manifestations appear when at least two of the three hepatic veins are occluded 8.
Budd-Chiari syndrome is rare. A Japanese study estimated the prevalence to be in the region of 2.4 cases/million 4. In Asian countries, there is a male predilection 9. In Western populations, it is most commonly diagnosed in females in the third and fourth decades and the most common cause is thrombosis 9. Membranous webs have been increasingly described in Asian patients as a cause of obstruction.
The classic acute presentation is with the clinical triad of ascites, hepatomegaly, and abdominal pain, although this is non-specific. The presentation may be acute or chronic:
acute: results from an acute thrombosis of the main hepatic veins or the inferior vena cava; patients may present with rapid onset ascites
chronic: the chronic form is related to fibrosis of the intrahepatic veins, presumably related to inflammation
The etiology is mixed and varied. The majority of cases result from thrombosis within the hepatic veins. However, 25% arise from external compression that results in obstruction:
idiopathic (one-third of cases)
venous thrombosis secondary to
injury and/or inflammation secondary to
It may be associated with concurrent portal vein thrombosis.
It is characterized on imaging by ascites, caudate hypertrophy, peripheral atrophy, and prominent collateral veins.
no flow or inappropriately directed flow in the right hepatic vein or a part of it
discontinuity between the main hepatic vein and the inferior vena cava
reversed flow in hepatic veins
intra- and extrahepatic collaterals
portal vein changes e.g. hepatofugal flow
low or absent flow in the inferior vena cava or balanced bidirectional flow
bland thrombus or tumor thrombus within the inferior vena cava
increased resistive index within the hepatic artery: >0.75
early enhancement of the caudate lobe and central liver around the inferior vena cava
delayed enhancement of the peripheral liver with accompanying central low density (flip-flop appearance)
inhomogeneous mottled liver (nutmeg liver)
peripheral zones of the liver may appear hypoattenuating because of reversed portal venous blood flow
inability to identify hepatic veins
in the chronic phase, there is caudate lobe enlargement and atrophy of the peripheral liver in affected areas
complete occlusion of hepatic veins
may or may not be associated with a (focal) stenosis of the intrahepatic inferior vena cava
spider web appearance of the intrahepatic collateral veins
Treatment and prognosis
If left untreated, progression to liver failure from fibrosis and eventual death may occur. Management options include 10:
long-term anticoagulation (is usually a first option of treatment)
liver transplantation (definitive treatment)
surgical portosystemic shunting
hepatic venoplasty with stenting
IVC-plasty with stenting
as a bridging therapy prior to liver transplantation or surgical portosystemic shunting
as a treatment for patients with contraindications for liver transplantation
Patients with chronic Budd-Chiari syndrome are at risk for hepatocellular carcinoma (HCC) and therefore should be monitored with serum alpha-fetoprotein (AFP) 5.
History and etymology
Initially described by George Budd (1808-1882) in 1845 before Hans Chiari (1851-1916) lent his first pathological description of "obliterating endophlebitis of the hepatic veins" in 1899.
- 1. Murphy F, Steinberg H, Shires G, Martin L, Bernardino M. The Budd-Chiari Syndrome: A Review. AJR Am J Roentgenol. 1986;147(1):9-15. doi:10.2214/ajr.147.1.9 - Pubmed
- 2. Brancatelli G, Vilgrain V, Federle M et al. Budd-Chiari Syndrome: Spectrum of Imaging Findings. AJR Am J Roentgenol. 2007;188(2):W168-76. doi:10.2214/AJR.05.0168 - Pubmed
- 3. Cura M, Haskal Z, Lopera J. Diagnostic and Interventional Radiology for Budd-Chiari Syndrome. Radiographics. 2009;29(3):669-81. doi:10.1148/rg.293085056 - Pubmed
- 4. Okuda H, Yamagata H, Obata H et al. Epidemiological and Clinical Features of Budd-Chiari Syndrome in Japan. J Hepatol. 1995;22(1):1-9. doi:10.1016/0168-8278(95)80252-5 - Pubmed
- 5. Vilgrain V, Paradis V, Van Wettere M, Valla D, Ronot M, Rautou P. Benign and Malignant Hepatocellular Lesions in Patients with Vascular Liver Diseases. Abdom Radiol (NY). 2018;43(8):1968-77. doi:10.1007/s00261-018-1502-7 - Pubmed
- 6. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari Syndrome: A Common Complication of Behçet's Disease. Am J Gastroenterol. 1997;92(5):858-62. - Pubmed
- 7. Shukla A, Parikh H, Modi T et al. Hepatic Vein Obstruction is the Most Common Type of Hepatic Venous Outflow Obstruction Regardless of Socioeconomic Status. Ann Gastroenterol. 2015;28(1):130-4. PMC4289986 - Pubmed
- 8. Giuseppe Orlando. Regenerative Medicine Applications in Organ Transplantation. (2013) ISBN: 9780123985231 - Google Books
- 9. Asif A. Hitawala & Vikas Gupta. Budd Chiari Syndrome. StatPearls Publishing. 2021. https://www.ncbi.nlm.nih.gov/books/NBK558941/ - Pubmed
- 10. Sharma A, Keshava S, Eapen A, Elias E, Eapen C. An Update on the Management of Budd-Chiari Syndrome. Dig Dis Sci. 2021;66(6):1780-90. doi:10.1007/s10620-020-06485-y - Pubmed